Thrivent Financial for Lutherans’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.78M Sell
9,715
-4,272
-31% -$787K ﹤0.01% 1537
2025
Q4
$2.46M Sell
13,987
-68,104
-83% -$11.1M ﹤0.01% 1340
2025
Q3
$11.5M Buy
82,091
+63,896
+351% +$8.64M 0.02% 574
2025
Q2
$2.29M Buy
18,195
+3,544
+24% +$442K 0.01% 1262
2025
Q1
$2M Sell
14,651
-1,185
-7% -$169K ﹤0.01% 1286
2024
Q4
$2.42M Sell
15,836
-172,817
-92% -$29.1M ﹤0.01% 1296
2024
Q3
$36.6M Sell
188,653
-3,854
-2% -$806K 0.07% 327
2024
Q2
$44.6M Sell
192,507
-8,889
-4% -$1.93M 0.09% 277
2024
Q1
$43.4M Sell
201,396
-57,961
-22% -$13.6M 0.09% 282
2023
Q4
$67.1M Sell
259,357
-21,290
-8% -$5.23M 0.15% 204
2023
Q3
$72.1M Sell
280,647
-8,657
-3% -$2.32M 0.17% 161
2023
Q2
$82.4M Sell
289,304
-7,838
-3% -$2.33M 0.19% 155
2023
Q1
$82.6M Sell
297,142
-1,466
-0.5% -$406K 0.2% 145
2022
Q4
$82.7M Sell
298,608
-10,214
-3% -$2.88M 0.21% 127
2022
Q3
$82.5M Buy
308,822
+47,482
+18% +$10.1M 0.23% 112
2022
Q2
$53.3M Sell
261,340
-8,904
-3% -$1.82M 0.14% 192
2022
Q1
$56.9M Buy
270,244
+10,967
+4% +$2.38M 0.11% 226
2021
Q4
$62.2M Buy
259,277
+31,661
+14% +$8.14M 0.12% 217
2021
Q3
$64.4M Buy
227,616
+37,331
+20% +$12.2M 0.13% 195
2021
Q2
$65.9M Buy
190,285
+29,693
+18% +$9M 0.13% 195
2021
Q1
$44.9M Buy
160,592
+7,208
+5% +$1.94M 0.1% 252
2020
Q4
$37.6M Sell
153,384
-6,441
-4% -$1.66M 0.09% 291
2020
Q3
$45.3M Sell
159,825
-6,971
-4% -$1.94M 0.12% 205
2020
Q2
$44.6M Sell
166,796
-3,871
-2% -$1.16M 0.13% 192
2020
Q1
$54M Buy
170,667
+79,761
+88% +$24.2M 0.19% 127
2019
Q4
$27M Buy
90,906
+11,337
+14% +$3.15M 0.08% 298
2019
Q3
$18.5M Sell
79,569
-34,912
-30% -$8.13M 0.06% 346
2019
Q2
$26.8M Sell
114,481
-156,478
-58% -$36.1M 0.08% 278
2019
Q1
$64M Sell
270,959
-174,100
-39% -$54.8M 0.2% 133
2018
Q4
$134M Buy
445,059
+13,623
+3% +$4.35M 0.48% 41
2018
Q3
$152M Sell
431,436
-3,571
-0.8% -$1.23M 0.48% 39
2018
Q2
$126M Buy
435,007
+143,962
+49% +$40.5M 0.41% 49
2018
Q1
$79.7M Sell
291,045
-18,425
-6% -$5.72M 0.27% 86
2017
Q4
$98.6M Sell
309,470
-826
-0.3% -$265K 0.33% 66
2017
Q3
$97.2M Buy
310,296
+69,173
+29% +$20.5M 0.34% 66
2017
Q2
$65.4M Sell
241,123
-2,097
-0.9% -$554K 0.27% 94
2017
Q1
$66.5M Buy
243,220
+191,910
+374% +$54.3M 0.29% 84
2016
Q4
$14.6M Buy
51,310
+22,770
+80% +$6.75M 0.06% 294
2016
Q3
$8.93M Buy
28,540
+21,769
+322% +$6.45M 0.04% 418
2016
Q2
$1.64M Buy
6,771
+401
+6% +$106K 0.01% 937
2016
Q1
$1.66M Buy
6,370
+100
+2% +$26.4K 0.01% 925
2015
Q4
$1.92M Sell
6,270
-130
-2% -$37.4K 0.01% 864
2015
Q3
$1.87M Buy
6,400
+300
+5% +$99.1K 0.01% 809
2015
Q2
$2.46M Sell
6,100
-2,100
-26% -$843K 0.01% 623
2015
Q1
$3.46M Sell
8,200
-20,350
-71% -$8.02M 0.02% 566
2014
Q4
$9.69M Sell
28,550
-1,400
-5% -$453K 0.05% 330
2014
Q3
$9.91M Sell
29,950
-8,150
-21% -$2.69M 0.06% 312
2014
Q2
$12M Buy
38,100
+32,600
+593% +$9.81M 0.07% 294
2014
Q1
$1.68M Hold
5,500
0.01% 628
2013
Q4
$1.54M Sell
5,500
-31,300
-85% -$8.1M 0.01% 664
2013
Q3
$8.86M Sell
36,800
-930
-2% -$208K 0.06% 329
2013
Q2
$8.12K Buy
+37,730
New +$8.06M 0.05% 349

Other funds holding BIIB

Thrivent Financial for Lutherans's BIIB Position: Q1 2026 in Review

Thrivent Financial for Lutherans reduced its Biogen (BIIB) stake by 31% in Q1 2026, selling an estimated $787K and leaving 9,715 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1537.

Thrivent Financial for Lutherans first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $152M in Q3 2018. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Thrivent Financial for Lutherans held 9,715 shares of Biogen worth $1.78M as of Q1 2026.
  • Thrivent Financial for Lutherans sold 4,272 Biogen shares in Q1 2026, an estimated $787K.
  • Biogen made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #1537 holding.
  • Thrivent Financial for Lutherans first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Thrivent Financial for Lutherans's Biogen position peaked at $152M in Q3 2018.
  • 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.